{"product_id":"cmmb-vrio-analysis","title":"Chemomab Therapeutics Ltd. (CMMB): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Chemomab Therapeutics Ltd. (CMMB) truly built to last? Dive into this essential VRIO analysis to instantly see if their core assets possess the Value, Rarity, Inimitability, and Organization needed to dominate the market. The answers determining their sustainable competitive advantage are just below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemomab Therapeutics Ltd. (CMMB) - VRIO Analysis: Nebokitug (CM-101) Composition of Matter Patent Estate\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at the core intellectual property protecting Nebokitug (formerly CM-101), and honestly, it’s the bedrock of the company's valuation right now, especially given the positive Phase 2 SPRING trial data and the aligned FDA pathway for a single pivotal Phase 3 trial. The patent estate is what lets Chemomab Therapeutics Ltd. command a premium if this drug gets to market for Primary Sclerosing Cholangitis (PSC).\u003c\/p\u003e\n\n\u003ch\u003eValue: Legal Monopoly and Pricing Power\u003c\/h\u003e\n\u003cp\u003eThe composition of matter patent provides a legal monopoly, which is essential because it lets Chemomab Therapeutics Ltd. price Nebokitug without immediate generic competition for the core therapeutic mechanism. This exclusivity is what drives peak sales projections. For instance, the US composition of matter patent is not expected to expire before \u003cstrong\u003e2035\u003c\/strong\u003e, which is a significant runway. This protection is what allows you to project significant peak sales, unlike a product relying only on method-of-use patents.\u003c\/p\u003e\n\n\u003ch\u003eRarity: First-in-Class Mechanism\u003c\/h\u003e\n\u003cp\u003eNebokitug, as a monoclonal antibody targeting CCL24, is inherently rare because it’s a first-in-class agent in this space. There isn't another drug in the market right now that blocks CCL24 to treat PSC. This rarity is validated by the clinical success; the Q1 2025 results showed continued biomarker improvements, reinforcing its unique position. The company's cash position as of March 31, 2025, was \u003cstrong\u003e$10.6 million\u003c\/strong\u003e, which they expect will fund operations through the second quarter of 2026 while they advance partnering options for the Phase 3 trial. That's the near-term risk: needing capital to bridge to the next value inflection point.\u003c\/p\u003e\n\n\u003ch\u003eImitability: High Barrier to Entry\u003c\/h\u003e\n\u003cp\u003eReplicating a complex biologic like a monoclonal antibody is not like copying a small molecule drug; it’s difficult and time-consuming. Proving non-infringement on the exact structure of Nebokitug adds another layer of defense. It takes years and millions of dollars to even attempt to design around the core claims. This high barrier to entry means competitors face a steep uphill battle, even if they target the same disease pathway. Defintely, the complexity here is a major moat.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Active Portfolio Expansion\u003c\/h\u003e\n\u003cp\u003eChemomab Therapeutics Ltd. is actively organizing around this asset by aggressively securing new patents in key commercial territories. Just in 2025, they added new patent protections in China and Russia, extending coverage for use patents up to \u003cstrong\u003e2041\u003c\/strong\u003e. This shows management is focused on maximizing the duration of protection globally, which is crucial for securing favorable partnership terms for the planned Phase 3 registrational trial. The structure is there to support commercialization when the time comes.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the concrete protection dates you are working with:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eJurisdiction\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003ePatent Type\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eFirst to Expire Claim Year (Approx.)\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eUS\u003c\/td\u003e\n    \u003ctd\u003eComposition of Matter (CM-101)\u003c\/td\u003e\n    \u003ctd\u003eBefore \u003cstrong\u003e2035\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eBrazil\u003c\/td\u003e\n    \u003ctd\u003eComposition of Matter\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2035\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eUS\u003c\/td\u003e\n    \u003ctd\u003eUse (Hepatic Disease)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2038\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eChina\u003c\/td\u003e\n    \u003ctd\u003eUse (Hepatic Disease)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2038\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRussia\u003c\/td\u003e\n    \u003ctd\u003eMethod of Treatment\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2041\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eCompetitive Advantage: Sustained Protection\u003c\/h\u003e\n\u003cp\u003eThe composition of matter patent, supported by the use patents extending protection into the \u003cstrong\u003e2040s\u003c\/strong\u003e in key areas, provides the longest-term, strongest protection - a \u003cstrong\u003esustained\u003c\/strong\u003e competitive advantage. This is the gold standard in pharma IP. What this estimate hides, however, is the risk that the Phase 3 trial might not meet its endpoint, which would render the patent value moot regardless of its expiration date. The R\u0026amp;D expenses for Q2 2025 were \u003cstrong\u003e$1.3 million\u003c\/strong\u003e, showing the burn rate is managed as they prepare for the next big step.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft the updated 13-week cash flow view incorporating Q3 2025 burn projections by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemomab Therapeutics Ltd. (CMMB) - VRIO Analysis: FDA\/EMA Regulatory Alignment for Single Pivotal PSC Trial\n\u003c\/h2\u003e\n\u003cp\u003eThe regulatory alignment achieved with the U.S. Food and Drug Administration (FDA) for nebokitug in Primary Sclerosing Cholangitis (PSC) represents a critical strategic asset.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eVRIO Framework Assessment:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDramatically de-risks the path to market\u003c\/td\u003e\n\u003ctd\u003eSingle pivotal Phase 3 trial pathway secured; No liver biopsies or additional confirmatory studies required.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eVery high\u003c\/td\u003e\n\u003ctd\u003eAchieved alignment on a single, clinical-event-driven pivotal trial for PSC, a disease with no FDA-approved therapies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eVery high\u003c\/td\u003e\n\u003ctd\u003eRegulatory decisions are specific to the data package from the Phase 2 SPRING trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eExcellent\u003c\/td\u003e\n\u003ctd\u003eManagement successfully navigated the End-of-Phase 2 meeting to secure this streamlined path.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eSupporting Data and Metrics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Status \u0026amp; Pathway:\u003c\/strong\u003e\n\u003cul\u003e\n\u003cli\u003eAlignment with FDA on a single Phase 3 registration study for nebokitug in PSC.\u003c\/li\u003e\n\u003cli\u003eThe single pivotal trial is designed to support full regulatory approval.\u003c\/li\u003e\n\u003cli\u003eThe trial does not require liver biopsies or additional confirmatory studies.\u003c\/li\u003e\n\u003cli\u003eNebokitug holds FDA and EMA Orphan Drug designations and FDA Fast Track designation for PSC treatment.\u003c\/li\u003e\n\u003cli\u003eThe Phase 3 primary endpoint assesses time-to-first-event encompassing multiple clinical events associated with disease progression.\u003c\/li\u003e\n\u003cli\u003eThe planned Phase 3 trial anticipates enrolling approximately 350 PSC patients.\u003c\/li\u003e\n\u003cli\u003eDiscussions are ongoing with the European Medicines Agency (EMA), with anticipation that the FDA-agreed protocol will support European approvals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePhase 2 SPRING Trial Context:\u003c\/strong\u003e\n\u003cul\u003e\n\u003cli\u003eThe Phase 2 SPRING trial involved 76 patients across 33 sites in five countries.\u003c\/li\u003e\n\u003cli\u003ePositive 48-week Open Label Extension data confirmed improvements across key biomarkers of liver injury, inflammation, and fibrosis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Context (as of March 31, 2025):\u003c\/strong\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and short-term bank deposits totaled $10.6 million.\u003c\/li\u003e\n\u003cli\u003eProjected cash runway extends through the second quarter of 2026.\u003c\/li\u003e\n\u003cli\u003eNet Loss for the first quarter of 2025 was $3.3 million.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) Expenses for the first quarter of 2025 were $2.5 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this regulatory precedent is locked in and provides a significant first-mover advantage in a market lacking FDA-approved therapies.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemomab Therapeutics Ltd. (CMMB) - VRIO Analysis: Positive Phase 2 SPRING Trial Data (Efficacy\/Safety)\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the clinical data generated from the nebokitug Phase 2 SPRING trial in Primary Sclerosing Cholangitis (PSC).\u003c\/p\u003e\n\n\u003ch\u003eValue: Provides the necessary proof-of-concept to attract strategic partners and support Phase 3 design assumptions.\u003c\/h\u003e\n\u003cp\u003eThe data demonstrated favorable safety and consistency in biomarker improvements, supporting the path toward a pivotal trial.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNebokitug was generally safe and well tolerated through 48 weeks of treatment in the Open-Label Extension (OLE).\u003c\/li\u003e\n\u003cli\u003eThe study supported the design of a single Phase 3 registration study following alignment with the FDA.\u003c\/li\u003e\n\u003cli\u003eThe drug candidate has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment.\u003c\/li\u003e\n\u003cli\u003eThe planned Phase 3 trial is designed to enroll approximately 350 PSC patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTrial Metric\u003c\/th\u003e\n\u003cth\u003eDetail\/Result\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Design\u003c\/td\u003e\n\u003ctd\u003eDouble-blind randomized study (\u003cstrong\u003en=76\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTreatment Arms\u003c\/td\u003e\n\u003ctd\u003eIV nebokitug \u003cstrong\u003e10 mg\/kg\u003c\/strong\u003e and \u003cstrong\u003e20 mg\/kg\u003c\/strong\u003e vs placebo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDuration\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e15 weeks\u003c\/strong\u003e (double-blind) with OLE up to \u003cstrong\u003e48 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Efficacy Finding (15 Weeks)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eStatistically significant reductions in liver stiffness (LSM)\u003c\/strong\u003e in moderate\/advanced fibrosis subgroup\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomarker Durability\u003c\/td\u003e\n\u003ctd\u003eDurable reductions in ELF and PRO-C3 sustained to 48 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity: Moderate; positive Phase 2 data is common, but showing improvements across fibrotic, inflammatory, and cholestatic markers is less so.\u003c\/h\u003e\n\u003cp\u003eNebokitug is a first-in-class antibody that inhibits the soluble protein CCL24, a key driver in fibro-inflammatory diseases.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Temporary; competitors could generate similar data with a superior molecule, but this data is proprietary.\u003c\/h\u003e\n\u003cp\u003eThe specific dataset, including the 48-week OLE results and the mechanism-of-action insights presented at AASLD The Liver Meeting® 2025, is proprietary to Chemomab.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Strong; data was presented at major meetings like AASLD The Liver Meeting® 2025, maximizing visibility.\u003c\/h\u003e\n\u003cp\u003eThe data was presented at the AASLD The Liver Meeting® 2025. Three presentations were designated as Posters of Distinction. The results were also published in the American Journal of Gastroenterology (publication date Nov 19, 2025).\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Temporary; the advantage erodes as Phase 3 data becomes the new benchmark.\u003c\/h\u003e\n\u003cp\u003eThe current advantage is based on positive Phase 2 results supporting the Phase 3 design, which will set the next benchmark for regulatory approval in PSC, a disease with no current FDA-approved therapies. The stock price as of December 6, 2025, was $2.4800, with a Market Cap of $13,314,072, against a 1-Year Target of $26.50.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemomab Therapeutics Ltd. (CMMB) - VRIO Analysis: Targeting CCL24 Pathway for Fibro-Inflammatory Diseases\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eTargeting CCL24 Pathway for Fibro-Inflammatory Diseases\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Establishes a deep, scientifically validated platform technology around a key driver of fibrosis and inflammation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCM-101 (Nebokitug) Phase 2 SPRING trial in Primary Sclerosing Cholangitis (PSC) demonstrated positive results across surrogate biomarker endpoints under consideration for accelerated approval.\u003c\/li\u003e\n\u003cli\u003eChemomab has reported positive results from four clinical trials of nebokitug in patients.\u003c\/li\u003e\n\u003cli\u003eThe CM-101 Phase 2a Liver Fibrosis trial in NASH patients met its primary endpoint of safety and tolerability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while the target is known, the specific, validated therapeutic approach via CCL24 neutralization is unique to Chemomab.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDisease Indication\u003c\/th\u003e\n\u003cth\u003eStudy Cohort Size\u003c\/th\u003e\n\u003cth\u003eKey CCL24 Finding\u003c\/th\u003e\n\u003cth\u003eDrug Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Sclerosing Cholangitis (PSC)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Proteomic Analysis)\u003c\/td\u003e\n\u003ctd\u003eHigh CCL24 linked to \u003cstrong\u003eCirrhosis\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCM-101 (Nebokitug) Phase \u003cstrong\u003e2\u003c\/strong\u003e completed; Phase \u003cstrong\u003e3\u003c\/strong\u003e design aligned with FDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSystemic Sclerosis (SSc)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\u0026gt;200\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eOne in four\u003c\/strong\u003e patients had high CCL24 despite standard of care\u003c\/td\u003e\n\u003ctd\u003eCM-101 Program \u003cstrong\u003ePhase 2-ready\u003c\/strong\u003e (US IND open)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors could pursue other anti-fibrotic targets, but blocking CCL24 specifically is proprietary knowledge.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe SSc longitudinal study showed high serum CCL24 was predictive of lung deterioration and higher baseline CCL24 was associated with higher 10-year SSc-related mortality.\u003c\/li\u003e\n\u003cli\u003eThe company secured gross proceeds of approximately \u003cstrong\u003e$10 million\u003c\/strong\u003e in a private placement in July 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; supported by peer-reviewed publications confirming CCL24’s pivotal role in PSC and SSc.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTopline data from the CM-101 Phase 2 PSC trial was reported in July 2024, approximately six months ahead of schedule.\u003c\/li\u003e\n\u003cli\u003eCash runway was extended to the beginning of \u003cstrong\u003e2026\u003c\/strong\u003e following the July 2024 financing.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and short-term bank deposits were \u003cstrong\u003e$19.5 million\u003c\/strong\u003e as of September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eThe company aligned with the FDA on the design of a single pivotal Phase 3 registration trial for nebokitug in PSC.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; a deep understanding of a novel, validated pathway is hard to build quickly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC.\u003c\/li\u003e\n\u003cli\u003eThe weighted average number of ordinary shares outstanding, basic and diluted, was \u003cstrong\u003e350,643,531\u003c\/strong\u003e for the third quarter of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemomab Therapeutics Ltd. (CMMB) - VRIO Analysis: Orphan Drug\/Fast Track Designations for PSC\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Offers regulatory incentives like market exclusivity post-approval and potential tax credits, improving net present value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eOrphan Drug Tax Credit: Equals 25% of qualified clinical testing expenses incurred in the U.S.\u003c\/li\u003e\n\u003cli\u003ePSC has no FDA-approved treatment currently.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; these designations are granted based on disease prevalence and unmet need, not just company quality.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\u003cli\u003ePSC is a rare type of fibrotic liver disease that can cause cancer and early death.\u003c\/li\u003e\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very high; these are government designations that cannot be imitated.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; management successfully applied for and secured these valuable statuses early on.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRegulatory Status\/Metric\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDesignations Secured\u003c\/td\u003e\n\u003ctd\u003eFDA Orphan Drug, EMA Orphan Drug, FDA Fast Track\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Trial Size (SPRING)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003en=76\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Trial Enrollment Plan\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e350\u003c\/strong\u003e PSC patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Time to Event (No Intervention)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003etwo years\u003c\/strong\u003e to experience a clinically meaningful event\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidity Runway (as of June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eThrough the \u003cstrong\u003esecond quarter of 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the exclusivity period is finite, though valuable for initial market penetration.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\u003cli\u003eMarket exclusivity period duration is determined by regulatory grant post-approval.\u003c\/li\u003e\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemomab Therapeutics Ltd. (CMMB) - VRIO Analysis: Dual Indication Potential (PSC and SSc)\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue: Broadens the total addressable market and provides a potential secondary revenue stream if the SSc program advances.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eNebokitug (CM-101) targets fibro-inflammatory diseases with high unmet need in both indications. The PSC Phase 2 SPRING trial demonstrated positive 48-week OLE data, with over \u003cstrong\u003e90%\u003c\/strong\u003e of eligible patients choosing to continue treatment.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eDevelopment Status\u003c\/th\u003e\n\u003cth\u003eRegulatory Designations\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Sclerosing Cholangitis (PSC)\u003c\/td\u003e\n\u003ctd\u003ePhase 2 Completed; Preparing for Phase 3 Registrational Trial\u003c\/td\u003e\n\u003ctd\u003eFDA Fast Track Designation; FDA and EMA Orphan Drug Designation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSystemic Sclerosis (SSc)\u003c\/td\u003e\n\u003ctd\u003ePhase 2-Ready; Open U.S. IND\u003c\/td\u003e\n\u003ctd\u003eFDA and EMA Orphan Drug Designation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: Moderate; many drugs target one indication, but having an open U.S. IND for a second, related disease is a plus.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe dual orphan indication status for Nebokitug is supported by specific regulatory achievements:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA Fast Track designation for PSC.\u003c\/li\u003e\n\u003cli\u003eFDA and EMA Orphan Drug designation for both PSC and SSc.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: Moderate; requires parallel development expertise, which not all small biotechs possess.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe organizational capacity to manage parallel development is evidenced by recent financial and operational metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and short-term bank deposits: \u003cstrong\u003e$10.6 million\u003c\/strong\u003e as of March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eExpected cash runway through the \u003cstrong\u003eSecond Quarter of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D Expenses for Q1 2025: \u003cstrong\u003e$2.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss for Q1 2025: \u003cstrong\u003e$3.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: Good; the SSc program has an open U.S. IND, showing organizational capacity for multi-indication development.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eOrganizational alignment supports advancement in both programs simultaneously. The SSc program has an open U.S. IND, and the PSC program has aligned with the FDA on a streamlined Phase 3 pathway.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSSc Program Status: Open U.S. IND; FDA IND clearance received in February 2023 for a Phase 2 trial.\u003c\/li\u003e\n\u003cli\u003ePSC Phase 3 Plan: Single pivotal trial based on a clinical event primary endpoint.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization: Approximately \u003cstrong\u003e$12.9M\u003c\/strong\u003e (as of November 24, 2025).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Temporary; the SSc advantage is only sustained if the program successfully moves into later-stage trials.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe immediate advantage lies in the de-risked PSC program, which is positioned to potentially become the first FDA-approved therapy for PSC. The SSc program's advantage is contingent on progression beyond the current Phase 2-ready status.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemomab Therapeutics Ltd. (CMMB) - VRIO Analysis: Cash Runway through Q4 2026 (Liquidity Management)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides operational stability and negotiating leverage while advancing Phase 3 preparations, avoiding a fire-sale.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many clinical-stage companies struggle with liquidity; this provides a clear runway until the end of 2026.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a function of past financing and current burn rate, not a core skill.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; management reported \u003cstrong\u003e$10.2M\u003c\/strong\u003e in cash as of September 30, 2025, projecting runway into Q4 2026.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; this is a necessary condition, not a source of advantage, though running out of cash is a major disadvantage.\u003c\/p\u003e\n\u003cp\u003eThe following table details key financial figures related to the reported liquidity position:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount (Millions USD)\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Short-Term Deposits\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Short-Term Deposits\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.5\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Short-Term Deposits\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral \u0026amp; Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss for the Period\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional relevant statistical and financial data points supporting the liquidity assessment include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProjected cash runway extends through the end of the \u003cstrong\u003efourth quarter of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of \u003cstrong\u003e$1.7 million\u003c\/strong\u003e for the third quarter of \u003cstrong\u003e2025\u003c\/strong\u003e, compared to a net loss of \u003cstrong\u003e$3.5 million\u003c\/strong\u003e in the third quarter of 2024.\u003c\/li\u003e\n\u003cli\u003eOrdinary shares issued and outstanding as of September 30, 2025, were \u003cstrong\u003e492,409,320\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe American Depositary Share (ADS) ratio change, effective August 26, 2025, adjusted the ratio from one ADS to \u003cstrong\u003e20\u003c\/strong\u003e ordinary shares to one ADS to \u003cstrong\u003e80\u003c\/strong\u003e ordinary shares.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemomab Therapeutics Ltd. (CMMB) - VRIO Analysis: Experienced Clinical\/R\u0026amp;D Leadership Team (Post-Q2 2025 Hires)\n\u003c\/h2\u003e\n\u003cp\u003eThe assessment of the Experienced Clinical\/R\u0026amp;D Leadership Team, following appointments in Q2 2025, is detailed below based on the VRIO framework components.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eAppointment Date\u003c\/th\u003e\n\u003cth\u003eYears of Experience (Total\/Relevant)\u003c\/th\u003e\n\u003cth\u003eKey Contribution\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterim Chief Medical Officer\u003c\/td\u003e\n\u003ctd\u003eApril 15, 2025\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e25+\u003c\/strong\u003e years in discovery and clinical development\u003c\/td\u003e\n\u003ctd\u003eRejoined; previously Interim CMO in \u003cstrong\u003e2021-2022\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Development Officer\u003c\/td\u003e\n\u003ctd\u003eApril 15, 2025\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e25\u003c\/strong\u003e years in clinical drug development\u003c\/td\u003e\n\u003ctd\u003eContributed to the development of \u003cstrong\u003eeight approved pharmaceutical products\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Ensures the complex Phase 3 trial design and execution are managed by seasoned professionals, minimizing operational errors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; experienced talent in rare disease drug development is scarce and highly sought after.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; recruiting top talent like the Interim Chief Medical Officer and Chief Development Officer takes time and resources.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; recent key appointments in Q2 2025 show management is actively building the team for Phase 3 execution.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Expenses for Q2 2025 were \u003cstrong\u003e$1.3 million\u003c\/strong\u003e, a decrease from \u003cstrong\u003e$2.9 million\u003c\/strong\u003e in Q2 2024.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and short-term bank deposits were \u003cstrong\u003e$9.5 million\u003c\/strong\u003e as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eExisting liquidity is expected to fund operations through the \u003cstrong\u003esecond quarter of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOrdinary shares issued and outstanding as of June 30, 2025, totaled \u003cstrong\u003e413,851,140\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Phase 3 program is planned as a single pivotal trial based on a clinical event primary endpoint.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; key personnel can leave, but the assembled expertise is valuable now.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemomab Therapeutics Ltd. (CMMB) - VRIO Analysis: Geographic Patent Expansion (China\/Russia Patents)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Secures future commercial rights in major global markets, which is critical for maximizing partnership value.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; securing patents in China and Russia specifically for nebokitug is a targeted strategic move.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the process of securing patents in foreign jurisdictions is complex and time-consuming.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; the company reported these patents were issued on \u003cstrong\u003eJune 3, 2025\u003c\/strong\u003e, demonstrating proactive IP management alongside Q2 2025 financial reporting which showed a Net Loss of \u003cstrong\u003e$2.1 million\u003c\/strong\u003e and a cash position of \u003cstrong\u003e$9.5 million\u003c\/strong\u003e as of June 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; these territorial protections are locked in for the long haul.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eJurisdiction\u003c\/th\u003e\n\u003cth\u003ePatent Number\u003c\/th\u003e\n\u003cth\u003eCoverage Scope\u003c\/th\u003e\n\u003cth\u003eCoverage Expiration Year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003ctd\u003eZL 2018 8 0018207.8\u003c\/td\u003e\n\u003ctd\u003eUse in hepatic diseases, including PSC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2038\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRussia\u003c\/td\u003e\n\u003ctd\u003eRU 2022125176\u003c\/td\u003e\n\u003ctd\u003eMethod of Treatment Using Anti-CCL24 Antibodies (Formulations\/Doses)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2041\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe expansion reinforces the intellectual property portfolio, which is relevant for advancing potential partnerships to support a nebokitug Phase 3 registrational trial in PSC.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ2 2025 R\u0026amp;D expenses decreased to \u003cstrong\u003e$1.3M\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eCash position of \u003cstrong\u003e$9.5 million\u003c\/strong\u003e as of June 30, 2025, with runway through \u003cstrong\u003eQ2 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company issued \u003cstrong\u003e1,023,104\u003c\/strong\u003e ADSs under its ATM program in H1 2025, resulting in net proceeds of \u003cstrong\u003e$1.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e draft partnership valuation model sensitivity analysis by next Tuesday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516139724949,"sku":"cmmb-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/cmmb-vrio-analysis.png?v=1740159374","url":"https:\/\/dcf-model.com\/es\/products\/cmmb-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}